Earnings call transcript: Precision Optics' Q4 2025 revenue rise amid net loss

Precision Optics Corporation (POCI) reported Q4 2025 revenue of $6.2 million, a substantial sequential increase driven by key aerospace and medical device programs transitioning to production, yet annual revenue was flat at $19.1 million with a quarterly net loss of $1.4 million and an annual loss of $5.8 million. Despite current gross margin pressure (13% in Q4), the company projects significant improvement, forecasting FY2026 revenue of $25 million (30% growth) and gross margins of 30%, aiming for positive adjusted EBITDA of $500,000. This optimistic outlook, supported by operational efficiencies, tariff reimbursements, and a strong production backlog, contributed to a modest 2.27% aftermarket stock rise.

Analysis

Precision Optics Corporation (POCI) is at a critical inflection point, marked by a record-breaking fourth quarter revenue of $6.2 million, yet coupled with flat annual revenue of $19.1 million and a significant annual net loss of $5.8 million. The dichotomy in performance stems from the transition of two major programs to production. A high-margin aerospace program is scaling successfully, contributing nearly $2 million in Q4 with a strong $9 million backlog and mid-30% margins. Conversely, a high-volume single-use cystoscope program, despite reaching $800,000 in Q4 revenue, is operating at or below breakeven due to production yield issues and tariffs, severely compressing the company's overall gross margin to 13% for the quarter. Management has presented an aggressive turnaround plan for fiscal year 2026, forecasting revenue growth of over 30% to $25 million and a substantial gross margin recovery to approximately 30%. This optimistic guidance is underpinned by specific corrective actions, including a 24% near-term price increase and tariff cost pass-throughs for the underperforming medical contract, alongside the hiring of a new COO to drive manufacturing efficiencies. The projection of a return to positive adjusted EBITDA of approximately $500,000 hinges entirely on the successful execution of these operational and commercial initiatives, a significant challenge given the company's current cash position of just $1.8 million.

Key Decisions for Investors

• Consider POCI as a high-risk, execution-dependent turnaround story, where potential upside is contingent on management successfully delivering its FY2026 forecast of $25 million in revenue and a 30% gross margin.
• Investors should closely monitor quarterly gross margin improvements and cash burn, as progress on these fronts is the primary validation for the operational turnaround and crucial for mitigating financing risks associated with the low $1.8 million cash balance.
• Track the performance of the two key production programs, specifically looking for confirmation of margin recovery in the single-use cystoscope contract and sustained revenue growth from the high-margin aerospace program, as these are the core drivers of the FY2026 financial targets.
• Pay attention to the actions of the newly appointed COO and any reported gains in manufacturing efficiency, as this is a key pillar of the company's strategy to resolve the profitability issues that led to the current negative EBITDA.